ImmunoAIzer

ImmunoAIzer is a deep learning-based computational framework designed to enhance the understanding and treatment of cancer by analyzing the tumor microenvironment (TME). It achieves this by accurately predicting the spatial distribution of tumor-infiltrating lymphocytes (TILs), cancer cells, and key biomarkers and identifying gene mutations relevant to cancer progression and treatment responses.

The framework operates through two primary components: 1. A semi-supervised Cellular Biomarker Distribution Prediction Network (CBDPN) that predicts the spatial distribution of critical biomarkers such as CD3, CD20, PanCK, and DAPI within the TME, achieving an accuracy of 90.4%. This component allows for detailed mapping of the cellular composition within tumors, providing insights into the immune landscape surrounding cancer cells.

2. A Multilabel Tumor Gene Mutation Detection Network (TGMDN) that utilizes selected tumor areas from hematoxylin and eosin (H&E) stained tissue slides to detect mutations in genes such as APC, KRAS, and TP53. This network demonstrates its effectiveness through area-under-the-curve (AUC) values of 0.76, 0.77, and 0.79 for these mutations, respectively, indicating its reliable performance in identifying genetic alterations critical for cancer progression and treatment response.

ImmunoAIzer offers a comprehensive view of colon cancer's cellular and genetic landscapes, providing valuable information for guiding immunotherapy and prognosis. Its efficient and cost-effective approach to analyzing cell distribution and gene mutation status has the potential to aid in the decision-making process for cancer treatment significantly. Moreover, the generalizability of this method suggests it could be adapted for the study and treatment of other cancer types, making it a versatile tool in the fight against cancer.